NeuroVive Pharmaceutical ABのCurrent ratio
NeuroVive Pharmaceutical ABのCurrent ratioは何ですか。
NeuroVive Pharmaceutical ABのCurrent ratioは7.97です。
Current ratioの定義は何ですか。
流動比率は、同社が短期債務を履行するために十分なリソースを持っているかどうかを測定流動性比率です。
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
OTCのセクタHealth CareにおけるCurrent ratioの企業と比べるNeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical ABは何をしますか。
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
NeuroVive Pharmaceutical ABと類似のcurrent ratio
- Chesapeake GoldのCurrent ratioは7.95です。
- Eimco Elecon (India)のCurrent ratioは7.96です。
- Heng Tai ConsumablesのCurrent ratioは7.96です。
- Société Marseillaise du Tunnel Prado CarénageのCurrent ratioは7.97です。
- InvestSMARTのCurrent ratioは7.97です。
- The United Nilgiri Tea EstatesのCurrent ratioは7.97です。
- NeuroVive Pharmaceutical ABのCurrent ratioは7.97です。
- Bluegreen VacationsのCurrent ratioは7.97です。
- Hansoh PharmaceuticalのCurrent ratioは7.98です。
- Adverum Biotechnologies IncのCurrent ratioは7.99です。
- Diaceutics PLCのCurrent ratioは7.99です。
- Australian Unity Office FundのCurrent ratioは7.99です。
- Finolex CablesのCurrent ratioは7.99です。